目的:探讨在冠心病患者中应用曲美他嗪联合阿托伐他汀药物治疗的具体效用,明确其药物应用价值。方法:研究主题时间范围纳入确认为2022年9月~2023年9月,在此时间段确定入我院冠心病心绞痛患者,在符合研究信息标准条件后展开自愿参与筛选...目的:探讨在冠心病患者中应用曲美他嗪联合阿托伐他汀药物治疗的具体效用,明确其药物应用价值。方法:研究主题时间范围纳入确认为2022年9月~2023年9月,在此时间段确定入我院冠心病心绞痛患者,在符合研究信息标准条件后展开自愿参与筛选,确定60例,双盲法均分,每组各30例,以药物差异命名差别,分别为分析组(曲美他嗪联合阿托伐他汀),对比组(阿托伐他汀),以两组患者治疗前后疾病情况、炎症因子水平、内皮因子水平、治疗效果,作为试验参考数据分析。结果:治疗前,分析组和对比组患者疾病情况、炎症因子水平、内皮因子水平接近(p > 0.05);治疗后,分析组疾病情况、炎症因子水平、内皮因子水平、治疗效果更优(p Objective: This paper aims to investigate the specific efficacy of trimetazidine combined with atorvastatin in the treatment of patients with coronary heart disease, and to clarify its application value. Methods: The subject time range of the study was confirmed to be from September 2022 to September 2023. During this time period, patients with angina pectoris of coronary heart disease admitted to our hospital were identified, and after meeting the research information standard conditions, 60 patients were selected for voluntary screening. The patients were evenly divided by double-blind method, with 30 cases in each group. Naming the differences based on drug differences, they are the analysis group (trimetazidine combined with atorvastatin) and the comparison group (atorvastatin). Disease conditions, levels of inflammatory factors, levels of endothelial factors, and therapeutic effects of patients before and after treatment were used as reference data for trial analysis. Results: Before treatment, the disease status, levels of inflammatory factors and endothelial factors were similar between analysis group and comparison group (p > 0.05). After treatment, the disease status, inflammatory factor level, endothelial factor level and therapeutic effect of the analysis group were better (p < 0.05). Conclusion: In the current clinical treatment of coronary heart disease, trimetazidine combined with atorvastatin has the unique value of improving indicators such as inflammatory factors and endothelial factors in patients, and the effect is better than that of single drug application.展开更多
文摘目的:探讨在冠心病患者中应用曲美他嗪联合阿托伐他汀药物治疗的具体效用,明确其药物应用价值。方法:研究主题时间范围纳入确认为2022年9月~2023年9月,在此时间段确定入我院冠心病心绞痛患者,在符合研究信息标准条件后展开自愿参与筛选,确定60例,双盲法均分,每组各30例,以药物差异命名差别,分别为分析组(曲美他嗪联合阿托伐他汀),对比组(阿托伐他汀),以两组患者治疗前后疾病情况、炎症因子水平、内皮因子水平、治疗效果,作为试验参考数据分析。结果:治疗前,分析组和对比组患者疾病情况、炎症因子水平、内皮因子水平接近(p > 0.05);治疗后,分析组疾病情况、炎症因子水平、内皮因子水平、治疗效果更优(p Objective: This paper aims to investigate the specific efficacy of trimetazidine combined with atorvastatin in the treatment of patients with coronary heart disease, and to clarify its application value. Methods: The subject time range of the study was confirmed to be from September 2022 to September 2023. During this time period, patients with angina pectoris of coronary heart disease admitted to our hospital were identified, and after meeting the research information standard conditions, 60 patients were selected for voluntary screening. The patients were evenly divided by double-blind method, with 30 cases in each group. Naming the differences based on drug differences, they are the analysis group (trimetazidine combined with atorvastatin) and the comparison group (atorvastatin). Disease conditions, levels of inflammatory factors, levels of endothelial factors, and therapeutic effects of patients before and after treatment were used as reference data for trial analysis. Results: Before treatment, the disease status, levels of inflammatory factors and endothelial factors were similar between analysis group and comparison group (p > 0.05). After treatment, the disease status, inflammatory factor level, endothelial factor level and therapeutic effect of the analysis group were better (p < 0.05). Conclusion: In the current clinical treatment of coronary heart disease, trimetazidine combined with atorvastatin has the unique value of improving indicators such as inflammatory factors and endothelial factors in patients, and the effect is better than that of single drug application.
